Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Jun
14
2024
NNI EHS Research Strategy: 2024 Update Available for Public Comment Bergeson & Campbell, P.C.
Jun
14
2024
Supreme Court Rejects Challenge to FDA Approval of Mifepristone on Standing, but the Battle Continues Epstein Becker & Green, P.C.
Jun
14
2024
Client Alert: IARC to Evaluate Automotive Gasoline and Oxygenated Additives in Early 2025 Nelson Mullins
Jun
14
2024
Bump Stock Ruling May Presage Loper—and Clearer Answers to Immigration and Bankruptcy Questions - SCOTUS Today Epstein Becker & Green, P.C.
Jun
14
2024
McDermottPlus Check-Up: June 14, 2024 McDermott Will & Emery
Jun
14
2024
Supreme Court Unanimously Preserves Access to Mifepristone Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2024
Deadline to Register Cosmetic Facilities and List Cosmetic Products Fast Approaches ArentFox Schiff LLP
Jun
13
2024
FDA Wins Mifepristone Case, NLRB Denied Lower Injunctive Relief Standards, and “Trump Too Small” Denied Trademark - SCOTUS Today Epstein Becker & Green, P.C.
Jun
13
2024
Kroger Faces Civil Lawsuit Over Calorie Claims on Bread Products Keller and Heckman LLP
Jun
13
2024
Supreme Court Rejects Challenge to FDA Approval of Mifepristone: Impact on Health Plans Proskauer Rose LLP
Jun
13
2024
New Jersey Takes a “Trip” Towards Therapeutic Psilocybin: Just Don’t Pack Your Bags Yet! Norris McLaughlin P.A.
Jun
13
2024
Registration Opens for June 27, 2024, NNI Webinar on “What’s Next in NanoEHS: Risk Assessment and Risk Management” Bergeson & Campbell, P.C.
Jun
12
2024
EPA Finalizes Risk Management Rules for Asbestos and Methylene Chloride Hunton Andrews Kurth
Jun
12
2024
Nothing Fishy About Whole Foods’ Fish Oil Supplement Product Label Proskauer Rose LLP
Jun
12
2024
Making Sense of a Rare Robinson-Patman Act Plaintiffs’ Verdict McDermott Will & Emery
Jun
12
2024
FDA to Implement Reorganization of Human Foods Program by October 1 Keller and Heckman LLP
Jun
11
2024
BIPA Amendments + FTC Warns Automakers Blank Rome LLP
Jun
11
2024
Remote Patient Monitoring Innovating Health Tech: A Discussion with Dr. Vipul Kella Sheppard, Mullin, Richter & Hampton LLP
Jun
11
2024
FDA Draft Guidance for Bioresearch Monitoring Program Contains General Best Practices for FDA Inspections Greenberg Traurig, LLP
Jun
11
2024
Consumer Reports Finds High Lead Levels in Snacks for Young Children Keller and Heckman LLP
Jun
11
2024
Da Brat and The Latest (Rap) Battle: FDA Expected to Drop Sperm Donation Ban for Gay Men ArentFox Schiff LLP
Jun
10
2024
CODEX ALIMENTARIUS: Outcome of 17th Codex Committee on Toxins and Contaminants in Foods (CCCF17) Keller and Heckman LLP
Jun
10
2024
CODEX ALIMENTARIUS: Outcome of 54th Codex Committee on Food Hygiene (CCFH54) Keller and Heckman LLP
Jun
6
2024
LDT Final Rule Series: Part 1 – Rule Overview Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2024
LDT Final Rule Series: Part 2 – Response to the Rule Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2024
Federal Circuit Upholds Rifaximin Patent Rulings, Affirms ANDA Approval Restrictions Sheppard, Mullin, Richter & Hampton LLP
Jun
6
2024
For Statutory Equivalents, Even One Means May Be Enough McDermott Will & Emery
Jun
6
2024
FDA Shares Findings from Multi-Year Pathogen Study Keller and Heckman LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins